Clinical trials
Urinary Bladder Cancer clinical trials
Below are recruiting urinary bladder cancer clinical trials, each written for real people, not researchers. We’re tracking 165 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03108196Recruiting
Tested neobladder type after bladder cancer surgery
This trial compares two ways surgeons rebuild a new bladder using either sigmoid colon tissue or ileum (small intestine) tissue. It aims to see which option is safer and works better for people having bladder cancer surgery.
Guangzhou, GuangdongAges 18–100 - NCT06892860RecruitingPhase 2
Comparing shorter vs longer chemo before immunotherapy for bladder cancer
This trial is testing whether 3 cycles of chemotherapy are as effective as 6 cycles before starting maintenance immunotherapy (avelumab) for people with advanced bladder cancer. The goal is to see if a shorter chemo course can reduce side effects while still controlling the cancer.
ParisAges 18 years+ - NCT07119996RecruitingPhase 1
Vitamin B3 to boost immunotherapy for bladder cancer
This trial tests whether taking vitamin B3 can help immunotherapy work better for people with bladder cancer. It’s for patients who have a certain type of bladder cancer and have had a recent infection that needed antibiotics.
Guangzhou, GuangdongAges 18 years+ - NCT07749924Recruiting
Watchful waiting vs. bladder chemotherapy for intermediate-risk bladder cancer
This study compares two approaches for people with intermediate-risk bladder cancer whose urine shows no signs of cancer after surgery. One group will be watched closely (active surveillance), while the other will receive chemotherapy directly into the bladder (intravesical chemotherapy). The goal is to see if surveillance alone can prevent unnecessary treatment while keeping the cancer controlled.
DaqingAges 18 years+ - NCT06662071Recruiting
Personalized bladder cancer treatment using organoid drug testing
This trial tests if using a patient's own tumor cells grown in a lab (organoids) can help choose the best chemotherapy to put directly into the bladder. It is for people with non-muscle invasive bladder cancer who need their first round of this treatment.
Binzhou, ShandongAges 18–80 - NCT07122414RecruitingPhase 1/Phase 2
Testing a new drug for bladder cancer that resists BCG
This trial tests a new drug (FL115) given directly into the bladder, alone or with BCG, for people with a type of bladder cancer that has not responded to BCG therapy. It aims to find a better treatment option for those who cannot have or refuse bladder removal surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06427824Recruiting
Health tests for older adults with bladder cancer before bladder removal
This study looks at how a series of health tests (called a comprehensive geriatric assessment) can help doctors plan care for older adults with bladder cancer who are having their bladder removed. The goal is to improve recovery and quality of life.
Chicago, IllinoisAges 65 years+ - NCT06245603Recruiting
Testing Hydeal Cyst with standard treatment for bladder cancer
This study tests a bladder instillation called Hydeal Cyst, given alongside standard BCG or MMC therapy, to see if it helps reduce side effects or improve outcomes for people with non-muscle invasive bladder cancer.
BergamoAges 18 years+ - NCT05710848RecruitingPhase 1/Phase 2
Study drug for repeat bladder tumor surgery patients
This trial tests STM-416, given around the time you have surgery to remove recurring bladder tumors, to see if it can reduce the chance the cancer comes back. It is for people with high-risk early bladder cancer (non–muscle-invasive) who have already had standard treatment and now need another TURBT.
Mesa, ArizonaAges 18 years+ - NCT05002556Recruiting
Bladder cancer follow-up registry for adults in France
This trial is a real-world registry that collects information during follow-up for certain early-stage bladder cancer. It may help doctors understand how urinary test results relate to recurrence and guide monitoring over time.
Aix-en-ProvenceAges 18 years+ - NCT06929286RecruitingPhase 3
Gene therapy vs standard care for bladder cancer after BCG fails
This trial compares a gene therapy (nadofaragene firadenovec) against standard care for people with an early-stage bladder cancer that has not responded to BCG. The goal is to see if this treatment is more effective and possibly helps avoid bladder removal.
Baltimore, MarylandAges 21 years+ - NCT04626167RecruitingEarly Phase 1
Testing a bladder transplant done with a kidney transplant
This early-phase study is testing a combined bladder and kidney transplant approach for people whose bladder problems damage the kidneys. The goal is to see if this treatment can improve bladder and kidney outcomes and be done safely.
Rochester, MinnesotaAges 1–60 - NCT03945162RecruitingPhase 2
Bladder cancer trial using light therapy in the bladder
This Phase 2 study tests a treatment called photodynamic therapy (PDT) placed directly into the bladder. It may help people whose non–muscle-invasive bladder cancer did not respond to BCG treatment or could not tolerate it.
Chicago, IllinoisAges 18 years+ - NCT06525571RecruitingPhase 3
Blue light surgery for high-risk bladder cancer
This trial tests if using blue light during surgery helps remove all cancer in people with high-risk non-muscle invasive bladder cancer. It may lower the chance of the cancer coming back.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06814496RecruitingPhase 1/Phase 2
Radiation and immunotherapy combo for DLL3-positive cancers
This trial combines radiation with an immunotherapy drug called tarlatamab to treat cancers that make a protein called DLL3. The goal is to see if this combination works better than either treatment alone for people with certain types of lung cancer and other tumors that have not responded to prior therapy.
Gilbert, ArizonaAges 18–99 - NCT07218380RecruitingPhase 3
Study of Vepugratinib for advanced bladder or urinary tract cancer
This trial tests an experimental drug called Vepugratinib for people with advanced urinary tract cancer that has a specific change in the FGFR3 gene. It may be an option if you haven't had other treatments for advanced cancer and are looking for a new approach.
Tucson, ArizonaAges 18 years+ - NCT07660055RecruitingPhase 1
Radioactive drug for advanced solid tumors
This trial tests a new radioactive drug (called 177Lu-DWJ155) that targets and kills cancer cells, along with a similar imaging agent (68Ga-DWJ155) used to see where the drug goes in the body. It is for people with certain advanced solid tumors that have not responded to standard therapies.
Omaha, NebraskaAges 18 years+ - NCT07483970RecruitingPhase 1
JL19001 alone or with BCG for high-risk non-muscle invasive bladder cancer
This trial tests a new drug called JL19001, given alone or with BCG (a standard bladder cancer treatment), for people with high-risk bladder cancer that hasn't spread into the bladder muscle. The goal is to see if it can help prevent the cancer from coming back or getting worse.
Chengdu, SichuanAges 18 years+ - NCT07762586RecruitingPhase 2
Neoadjuvant chemotherapy for muscle-invasive bladder cancer
This study looks at how well a standard chemotherapy given before surgery works for muscle-invasive bladder cancer. It aims to see if higher responses lead to better outcomes.
New Brunswick, New JerseyAges 18–90 - NCT07077447Recruiting
Study on cancer in the upper urinary tract
This trial is for people diagnosed with a rare type of cancer in the upper urinary tract (UTUC). Researchers hope to learn more about this condition and find better ways to treat it.
Aarhus NAges 18 years+ - NCT06161506RecruitingPhase 2
Electrical stimulation for urinary incontinence after prostate cancer treatment
This trial tests a non-surgical, non-drug treatment that uses gentle electrical stimulation on the skin to help strengthen the muscles that control urine leakage. It's for men who still have urinary incontinence at least 6 months after their prostate cancer treatment.
Bethesda, MarylandAges 18–120 - NCT06511648RecruitingPhase 2
Erdafitinib with or without immunotherapy for FGFR-altered bladder cancer
This trial tests a targeted therapy called erdafitinib, either alone or combined with an immunotherapy drug (cetrelimab), for people with muscle-invasive bladder cancer that has a specific FGFR gene change. It may be an option if you cannot take cisplatin chemotherapy and have not had prior treatment for this cancer.
Clermont-FerrandAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Anchorage, AlaskaAges 18 years+ - NCT06161532RecruitingPhase 2
Sacituzumab govitecan with or without atezolizumab for rare GU cancers
This trial is testing a drug called sacituzumab govitecan, sometimes combined with atezolizumab (an immunotherapy), for rare cancers of the bladder, urinary tract, kidney, or penis. The goal is to see if these treatments work well for people whose cancers have not responded to other options.
Bethesda, MarylandAges 18–120
Hear when a new Urinary Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for urinary bladder cancer?
- Yes. Clin2 currently lists 165 recruiting urinary bladder cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a urinary bladder cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a urinary bladder cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.